Unity Biotechnology Competitors

4D Molecular Therapeutics (NASDAQ:FDMT) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and Unity Biotechnology's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for 4D Molecular Therapeutics and Unity Biotechnology, as reported by MarketBeat.

4D Molecular Therapeutics presently has a consensus target price of $45.50, suggesting a potential upside of 20.75%. Unity Biotechnology has a consensus target price of $4.80, suggesting a potential downside of 14.44%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than Unity Biotechnology.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares 4D Molecular Therapeutics and Unity Biotechnology's net margins, return on equity and return on assets.

Summary

4D Molecular Therapeutics beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Connect Biopharma Holdings Limited American Depositary Shares (NASDAQ:CNTB) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings & Valuation

This table compares Connect Biopharma Holdings Limited American Depositary Shares and Unity Biotechnology's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Connect Biopharma Holdings Limited American Depositary Shares and Unity Biotechnology, as reported by MarketBeat.

Connect Biopharma Holdings Limited American Depositary Shares presently has a consensus target price of $29.50, suggesting a potential upside of 69.05%. Unity Biotechnology has a consensus target price of $4.80, suggesting a potential downside of 14.44%. Given Connect Biopharma Holdings Limited American Depositary Shares' stronger consensus rating and higher probable upside, equities research analysts plainly believe Connect Biopharma Holdings Limited American Depositary Shares is more favorable than Unity Biotechnology.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Connect Biopharma Holdings Limited American Depositary Shares and Unity Biotechnology's net margins, return on equity and return on assets.

Summary

Connect Biopharma Holdings Limited American Depositary Shares beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Pharvaris B.V. and Unity Biotechnology, as reported by MarketBeat.

Pharvaris B.V. presently has a consensus target price of $47.50, suggesting a potential upside of 60.53%. Unity Biotechnology has a consensus target price of $4.80, suggesting a potential downside of 14.44%. Given Pharvaris B.V.'s stronger consensus rating and higher probable upside, equities research analysts plainly believe Pharvaris B.V. is more favorable than Unity Biotechnology.

Profitability

This table compares Pharvaris B.V. and Unity Biotechnology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Pharvaris B.V. and Unity Biotechnology's gross revenue, earnings per share and valuation.

Summary

Pharvaris B.V. beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Unity Biotechnology (NASDAQ:UBX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Unity Biotechnology and Bolt Biotherapeutics, as reported by MarketBeat.com.

Unity Biotechnology currently has a consensus price target of $4.80, suggesting a potential downside of 14.44%. Bolt Biotherapeutics has a consensus price target of $41.00, suggesting a potential upside of 71.12%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Unity Biotechnology.

Profitability

This table compares Unity Biotechnology and Bolt Biotherapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Unity Biotechnology and Bolt Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Bolt Biotherapeutics beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Unity Biotechnology (NASDAQ:UBX) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Unity Biotechnology and Gracell Biotechnologies, as reported by MarketBeat.com.

Unity Biotechnology currently has a consensus price target of $4.80, suggesting a potential downside of 14.44%. Gracell Biotechnologies has a consensus price target of $34.50, suggesting a potential upside of 166.62%. Given Gracell Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Gracell Biotechnologies is more favorable than Unity Biotechnology.

Profitability

This table compares Unity Biotechnology and Gracell Biotechnologies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Unity Biotechnology and Gracell Biotechnologies' revenue, earnings per share (EPS) and valuation.

Summary

Gracell Biotechnologies beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Unity Biotechnology (NASDAQ:UBX) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. Comparatively, 71.1% of iTeos Therapeutics shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Unity Biotechnology and iTeos Therapeutics, as reported by MarketBeat.com.

Unity Biotechnology currently has a consensus price target of $4.80, suggesting a potential downside of 14.44%. iTeos Therapeutics has a consensus price target of $49.40, suggesting a potential upside of 105.92%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe iTeos Therapeutics is more favorable than Unity Biotechnology.

Profitability

This table compares Unity Biotechnology and iTeos Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Unity Biotechnology and iTeos Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

iTeos Therapeutics beats Unity Biotechnology on 4 of the 5 factors compared between the two stocks.